Navigation Links
OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
Date:5/14/2009

ival benefit of OGX-011, anticipated clinical development activities, timing of these activities, the ability of future trials to demonstrate clinical benefit and the potential for regulatory approvals. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements.

The potential risks and uncertainties associated with forward-looking statements include, among others, the possibility that any benefit in patient survival will not be maintained or will become less substantial as patient survival follow up continues, risks that clinical trials will not be successful or confirm earlier clinical trial results, including the risk that the survival benefit will not be confirmed by a Phase 3 clinical trial, risks associated with obtaining funding from third parties or completing a financing necessary to support the costs and expenses of a Phase 3 clinical trial, the timing and costs of clinical trials and regulatory approvals will be different than management currently anticipates, risks relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products and the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for fiscal year 2008. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
2. OncoGenex Reports First Quarter Financial Results
3. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
4. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
5. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
6. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
7. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
8. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
9. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
10. OncoGenex Reports Third Quarter Financial Results
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... , May 1, 2015 Pfenex ... engaged in the development of biosimilar therapeutics including ... today that its first quarter 2015 financial results ... before the open of market. At 8:30 am Eastern ... to discuss the financial results and provide a ...
(Date:5/1/2015)... 2015 Investor-Edge has initiated ... (NASDAQ: GENE ), Agilent Technologies Inc. (NYSE: ... TMO ), Sequenom Inc. (NASDAQ: SQNM ... Free research report on Genetic Technologies can be ... 30, 2015, the NASDAQ Composite ended at 4,941.42, ...
(Date:5/1/2015)... RESEARCH TRIANGLE PARK, N.C. , May 1, 2015 /PRNewswire/ ... Roger Jeffs , Ph.D., President and Co-Chief Executive Officer ... the company,s business at the Deutsche Bank 40 th ... . The presentation will take place on Wednesday, ... be accessed via a live webcast on the United Therapeutics ...
(Date:4/30/2015)... DIEGO , April 30, 2015   Tamir ... announced today an update on its Ebola antiviral therapy ... Tamir,s leading candidates, TMR004, is currently being evaluated and ... of the battle against Ebola. During the first quarter ... And Leadership Meeting To Accelerate The Evaluation of Potential ...
Breaking Biology Technology:Pfenex To Report First Quarter 2015 Results and Provide Business Update on Thursday, May 14, 2015 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 4Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 5Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4
... the developing world could reduce the environmental impact of ... writing today in the Inderscience publication, International Journal of ... the developing world are encouraged to compost our garden ... bin and not all of us are willing or ...
... DENVER, Sept. 18 The future of health ... integrated into practice and,health policy. But putting research ... slow the pace of cutting-edge care. Kaiser,Permanente Colorado ... aimed at getting research into practice and policy ...
... Sept. 18 Kosan Biosciences,Incorporated (Nasdaq: KOSN ) ... and Chief Financial Officer, will present at the 2007,UBS ... Grand Hyatt on,Tuesday, September 25, 2007 at 10:00 a.m. ... of the presentation by,visiting the "Events Calendar" page under ...
Cached Biology Technology:Landfill Mining 2Kaiser Permanente Colorado Opens Center for Health Dissemination and Implementation Research 2Kosan Biosciences to Present at the 2007 UBS Global Life Sciences Conference 2
(Date:4/8/2015)... April 8, 2015  Infinisource, a leading provider ... and Morpho, a leading supplier of biometric identification ... the market,s most advanced biometrically-enabled time clock, the ... time clock is setting a bold, new standard ... for the small and mid-size employer. When connected ...
(Date:4/2/2015)... Germany , April 2, 2015 ... fingerprint tests DERMALOG by far outperforms the strongest ... always maintaining high accuracy, the system is capable ... Hence, the speed proves up to be ten ... faster than its runner-up performance.      ...
(Date:4/2/2015)... -- According to preliminary estimates Fingerprint Cards, ... than 125 MSEK. This exceeds the guidance provided by ... for Q1 2015 would be in line with the ... The operating result for the first quarter is estimated ... will as previously communicated be published on May 21. ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
... through which it can protect itself against newly-developing cancer ... in our organs every day. Once tumours have developed, ... from the immune system. Scientists from the research group ... (HZI) in Braunschweig have now succeeded to reveal a ...
... in the lungs of people who smoke may offer a ... emphysema before the disease damages and eventually destroys areas of ... The study found that smokers who have very subtle signs ... different blood flow patterns in their lungs compared to non-smokers ...
... April 6, 2010 Chronix Biomedical today announced publication ... serum DNA blood tests to predict clinical status and ... sclerosis (MS). Chronix Biomedical uses proprietary technology to ... that is released into the bloodstream by damaged and ...
Cached Biology News:The immune system's guard against cancer 2The immune system's guard against cancer 3New test could identify smokers at risk of emphysema 2Chronix Biomedical's serum DNA assays monitor disease activity and treatment response in MS 2Chronix Biomedical's serum DNA assays monitor disease activity and treatment response in MS 3
... product contains 5 ml Dynabeads® ... the monoclonal BerEP4 against the ... cell adhesion molecule). Also available ... 2 x 10e7 MNC in ...
albumin from bovine serum (BSA), tetramethylrhodamine conjugate...
Superior homology search software - in all the flavours of blast, with increased sensitivity and speed...
... Processing mini Tray (3 per pack), ... staining and blot processing.Automated staining of ... proteins and nucleic acid analysis.Prepares blots ... chromogenic detection.Programmable control of protocol, solution, ...
Biology Products: